SCT-650C

N/A

Report date: 2026/04/29 20:02:18

Base Information

Drug NameSCT-650C
Drug Alias NameSCT650CSCT-650-CSCT-650C
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionInterleukin 17A inhibitors
TargetsInterleukin 17A
Therapy Area/IndicationsPlaque psoriasisAxial SpondyloarthritisAutoimmune Diseases +[7
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryTurkeyAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesSinoCelltech Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesSinoCelltech Ltd
Inactive CompaniesN/A
Active IndicationsPlaque psoriasisAxial SpondyloarthritisAutoimmune Diseases +[7
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A